Colorectal Cancer

Final results of the DESTINY-CRC01 trial were consistent with primary analysis, establishing the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-overexpressing metastatic colorectal cancer.

Cetuximab added to mFOLFOXIRI induced superior depth of response than mFOLFOXIRI plus bevacizumab in treatment-naïve patients with RAS wild-type metastatic colorectal cancer.

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.

Some patients with previously treated advanced colorectal cancer responded to treatment with lenvatinib plus pembrolizumab.

Michael A. Choti, MD, discusses pursuing chemotherapy following tumor resection in advanced colorectal cancer.

Treatment approaches available for patients with newly diagnosed metastatic colorectal cancer that is RAS wild type and factors that impact decisions for utilizing a 2-drug versus 3-drug regimen.

Drs Jaffer A. Ajani and Zev A. Wainberg comment on the rationale for conducting full next-generation sequencing panels on patients with metastatic colorectal cancer and explain how to best utilize information provided to inform treatment decisions.

A significant incidence of advanced neoplasia and colorectal cancer was identified in individuals between the ages of 45 and 49 years, emphasizing the importance of adhering to recent recommendations from the United Services Preventive Services Task Force to lower the CRC screening age from 50 to 45 years.

Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.

Considerations regarding best sequencing strategies with novel therapies to treat HER2-mutated metastatic colorectal cancer.

Implications for treating patients with HER2-expressing metastatic colorectal cancer with novel agents such as trastuzumab deruxtecan and tucatinib.

Kanwal Raghav, MBBS, MD, discusses current sequencing approaches in metastatic colorectal cancer.

Screenings for breast cancer, colorectal cancer, and prostate cancer declined sharply from March to May 2020 vs the same time span in 2019, suggesting that public health efforts, such as increased use of screening modalities that do not require a procedure, are needed to address the deficit caused by the COVID-19 pandemic.

The significance of studying genomics in metastatic colorectal cancer and an overview of actionable targets that can be tested for to help in treatment decisions for newly diagnosed disease.

Dr Jaffer A. Ajani highlights the increasing incidence of colorectal cancer diagnoses in younger patients as a growing concern during a discussion on trends in prevalence.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the combination of nivolumab and ipilimumab as an option for patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer following fluoropyrimidine-based combination therapy.

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Current trials exploring novel combinations that show potential in making microsatellite stable tumors hot and amenable to response to immunotherapy in metastatic colon cancer.

Drs Cathy Eng and Joleen M. Hubbard discuss the rationale for studying dual immunotherapy approaches for metastatic colorectal cancer treatment.

Cathy Eng, MD, FACP, FASCO, discusses the rationale for studying the impact of RAS mutations in patients with early onset resectable colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses surgical considerations for patients with RAS-mutant colorectal cancer.

Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.

The use of universal tumor screening in conjunction with multigene panel testing led to an improvement in the identification of hereditary cancer syndromes in patients with colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the impact of RAS mutations on outcomes in patients with early vs late colorectal cancer following liver resection.

Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

Kanwal Raghav, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses when it is most appropriate to initiate immunotherapy for metastatic colorectal cancer, highlighting the roles of tumor mutation burden and microsatellite instability as biomarkers for treatment.

Cathy Eng, MD, FACP, FASCO, describes data revealed by the KEYNOTE-177 trial and discusses best practices for using immunotherapy as first-line treatment of metastatic colorectal cancer.

One in 6 patients with colorectal cancer harbor genetic changes that substantially increase their risk for cancer, especially in those who are younger at the time of diagnosis.

Three months of adjuvant capecitabine plus oxaliplatin represents a potential option for select patients with high-risk stage II colorectal cancer due to its convenience, reduced toxicity, and cost, although noninferiority to the 6-month standard duration was not demonstrated.